Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - HeFu China's closing price on May 7 was 6.63 yuan, with a PE ratio of 182.87, marking a new low in 21 days, and a total market capitalization of 2.639 billion yuan [1] - The average PE ratio for the pharmaceutical commercial industry is 36.32, with a median of 27.46, positioning HeFu China at 26th place within the industry [1][2] Group 2 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of HeFu China involves international trade and after-sales service of in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - In the latest quarterly report for Q1 2025, HeFu China reported revenue of 176 million yuan, a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, representing a year-on-year decline of 184.13%, with a gross profit margin of 16.71% [1]

A股医药商业板块异动拉升，嘉事堂封板涨停，瑞康医药、润达医疗、漱玉平民、合富中国、海王生物 等跟涨。 ...

扫码关注合富中国 合富（中国）医疗科技股份有限公司 上海市徐汇区虹漕路 456 号光启大厦 T（86）400-678-8855 www.cowealth.com 上海证券交易所 股票简称及代码：合富中国 603122 合富中国 2024 年度 可持续发展报告 合 富 中 国 2024 年 度 可 持 续 发 展 报 告 1 合富中国 2024 年度可持续发展报告 CMC 2024 Sustainability Report 报告发行时间 ：2025年4月 关于本报告 本报告编制 此为合富（中国）医疗科技股份有限公司（下称"合富中国"、 "本公司"、"公司"或"我们"）2024年的可持续发展报告（下称 本报告），旨在呈现本公司可持续发展的政策与绩效，以回应 利益相关方的期待。 本报告的编写参考以下报告指引 ： 我们以负责任的态度向利益相关方披露公司在经济、环境及社 会上的政策及表现，并展现本公司对落实可持续发展的决心。 报告范畴 本报告为年度报告，报告期为2024年1月1日至2024年12月31 日，提供合富中国重要营运地点的企业可持续发展管理与绩效 表现，主体范围与本公司年报一致。本报告部分统计资料引用 自年 ...

一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十五次会议于 2025 年 4 月 29 日下午在上海市虹漕路 456 号光启大楼 20 楼公司 董事会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合的方式召开， 会议通知于 2025 年 4 月 24 日以电子邮件或书面方式发出。本次会议由董事长李 惇先生主持，应到董事 7 人，实到董事 6 人，其中委托出席董事 1 人，非独立董 事王琼芝女士因工作安排委托董事长李惇先生代为出席本次会议并行使表决权； 缺席会议的董事 1 人，独立董事 Stanley Yi Chang 先生因个人身体健康原因缺 席本次会议。监事和部分高级管理人员列席了会议。会议的召开符合法律法规、 《公司法》及《公司章程》的规定，会议决议合法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 1 证券代码：603122 证券简称：合富中国 公告编号：临 2025-017 合富（中国）医疗科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及除独立董事 Stanley Yi C ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥175,735,762.62, a decrease of 26.35% compared to ¥238,622,168.70 in the same period last year[3] - The net profit attributable to shareholders was -¥6,001,192.11, representing a decline of 184.13% from a profit of ¥7,133,561.76 in the previous year[3] - Basic earnings per share decreased by 200.00% to -¥0.02 from ¥0.02 in the previous year[3] - Total revenue for Q1 2025 was RMB 175.74 million, a decrease of 26.4% compared to RMB 238.62 million in Q1 2024[16] - Net profit for Q1 2025 was a loss of RMB 5.89 million, compared to a profit of RMB 7.02 million in Q1 2024[17] - The company reported a total comprehensive loss of RMB 6.20 million in Q1 2025, compared to a comprehensive income of RMB 6.49 million in Q1 2024[17] Cash Flow and Operating Activities - The net cash flow from operating activities improved to ¥38,492,423.52, compared to -¥52,712,185.37 in the same period last year, indicating effective supply chain management[3] - Operating cash flow for Q1 2025 was RMB 38.49 million, a significant improvement from a negative cash flow of RMB -52.71 million in Q1 2024[19] - The company experienced a net cash outflow from investing activities of RMB 83.57 million in Q1 2025, compared to RMB -6.79 million in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,552,107,798.54, an increase of 3.88% from ¥1,494,072,333.88 at the end of the previous year[6] - The company's current assets totaled RMB 1,321,354,869.58, compared to RMB 1,290,982,272.60 at the end of 2024, indicating an increase of about 2.4%[13] - Total liabilities rose to RMB 383,911,181.84 from RMB 319,439,793.98, marking an increase of approximately 20.2%[14] - The company's equity attributable to shareholders decreased to RMB 1,165,160,559.65 from RMB 1,171,469,561.57, a decline of about 0.5%[14] - The total current liabilities increased to RMB 380,399,337.40 from RMB 318,701,872.45, reflecting a growth of approximately 19.4%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,527[10] - The company has not reported any changes in the top 10 shareholders or their participation in margin financing activities[12] Research and Development - Research and development expenses for Q1 2025 were RMB 635.17 thousand, a decrease of 30.6% from RMB 915.00 thousand in Q1 2024[16] Inventory and Receivables - The company reported a significant increase in inventory, which rose to RMB 208,529,372.68 from RMB 201,881,192.88, an increase of about 3.3%[13] - Accounts receivable increased to RMB 760,740,608.19 from RMB 738,471,128.95, representing a rise of approximately 3%[12] Non-Recurring Gains and Losses - Non-recurring gains and losses for the period totaled ¥43,497.32 after tax adjustments[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,044,689.43, a decline of 191.02% from ¥6,641,379.02 in the previous year[3] Equity and Return Metrics - The weighted average return on equity decreased to -0.51%, down 1.12 percentage points from 0.61% in the previous year[6] - The company's non-current assets totaled RMB 230,752,928.96, up from RMB 203,090,061.28, indicating an increase of approximately 13.6%[13]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-016 公司新一届董事会、监事会换届选举工作完成前，公司第二届董事会和监事 会全体成员、董事会各专门委员会委员及高级管理人员将按照法律法规和《公司 章程》的规定继续履行职责和义务。 公司董事会及监事会延期换届不会影响公司正常生产经营。公司将积极推进 董事会、监事会换届选举工作进程，并按照相关规定及时履行信息披露义务。 二、独立董事任期届满辞任情况 根据《上市公司独立董事管理办法》、《公司章程》等相关规定，上市公 司独立董事占董事会成员的比例不得低于三分之一，独立董事在上市公司连 续任职时间不得超过六年。公司现任独立董事 Stanley Yi Chang 先生、雷 永耀先生以及周露露女士任期将于 2025 年 4 月 27 日届满且连任时间将满六 年。近日，公司董事会收到独立董事 Stanley Yi Chang 先生、雷永耀先生 以及周露露女士的辞呈，提请辞去独立董事及董事会下属专门委员会的相关 职务，辞职后 Stanley Yi Chang 先生、雷永耀先生、周露露女士将不再担 任公司的任何职务。具体辞任情况如下： 独立董事 Stanley ...

4月14日，合富中国今日收盘6.36元，上涨1.27%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到91.84倍，总市值25.32亿元。 从行业市盈率排名来看，公司所处的医药商业行业市盈率平均22.48倍，行业中值19.59倍，合富中国排 名第28位。 截至2024年年报，共有15家机构持仓合富中国，其中基金12家、其他3家，合计持股数509.24万股，持 股市值0.36亿元。 合富(中国)医疗科技股份有限公司的主营业务是从事以体外诊断相关的医疗设备及其耗材为主的国际贸 易、售后服务，贸易代理，从事医院信息管理系统的咨询服务以及相关配套服务。公司的主要产品是体 外诊断产品集约化业务、医疗产品流通。 来源：金融界 最新一期业绩显示，2024年年报，公司实现营业收入9.39亿元，同比-14.05%；净利润2756.63万元，同 比-41.58%，销售毛利率19.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)28合富中国91.8491.842.1625.32亿行业平均 22.4822.651.81105.57亿行业中值19.5916.211.3057.29亿1漱玉平民-106.04 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-015 合富（中国）医疗科技股份有限公司 2025 年 1-3 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司 2025 年 1-3 月合并营业收入人民币 17,573.58 万元，较去年同期下降 26.35%，2025 年 1-2 月合并营业收入较去年同期下降 27.08%，下降幅度收窄 0.73%，营收情况持续改善。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2025 年 4 月 11 日 1 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn ...

合富中国（603122）公告，公司2025年1-3月合并营业收入为人民币1.76亿元，同比下降26.35%。2025 年1-2月合并营业收入较去年同期下降27.08%，下降幅度收窄0.73%，营收情况持续改善。 ...

Group 1 - The core viewpoint of the articles indicates that 合富中国 (Hefei China) is experiencing a significant decline in stock price and financial performance, with a current PE ratio of 98.34, which is substantially higher than the industry average of 22.15 [1][2] - As of the 2024 annual report, 合富中国 reported a revenue of 939 million yuan, representing a year-on-year decrease of 14.05%, and a net profit of 27.57 million yuan, down 41.58% from the previous year [1] - The company operates primarily in the field of in vitro diagnostic medical devices and related consumables, with its main products being concentrated in the in vitro diagnostic product business and medical product distribution [1] Group 2 - The total market capitalization of 合富中国 is 2.711 billion yuan, with 15 institutions holding shares, including 12 funds, totaling 5.0924 million shares valued at 36 million yuan [1] - In terms of industry comparison, 合富中国 ranks 28th in terms of PE ratio within the pharmaceutical commercial sector, where the median PE ratio is 17.56 [1][2] - The sales gross margin for 合富中国 stands at 19.60%, indicating the profitability of its sales relative to its revenue [1]